Form 4: Health Catalyst CFO Jason Alger Reports Stock Transactions
SEC Form 4 Filing
Jason Alger, CFO of Health Catalyst, reports the acquisition of 70,000 shares of common stock and the disposal of 2,474 shares to cover tax obligations.
Summary
- On March 1, 2024, Jason Alger, the Chief Financial Officer of Health Catalyst, Inc. (HCAT), reported transactions involving the company's common stock.
- Alger acquired 70,000 shares of common stock through an award of restricted stock units (RSUs) granted under the company's 2019 Stock Option and Incentive Plan.
- Each RSU represents a contingent right to receive one share of Health Catalyst's common stock.
- The RSUs vest over time, with 33.33% vesting on December 1, 2024, and the remaining 66.67% vesting in 8 equal quarterly installments.
- Alger also disposed of 2,474 shares of common stock at a price of $8.0512 per share.
- This disposal was to cover tax withholding obligations related to the vesting of restricted stock units and was mandated by the issuer's 'sell to cover' policy.
- Following these transactions, Alger beneficially owns 122,231 shares of Health Catalyst common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing primarily reports routine stock transactions. The acquisition of shares through RSUs is a mildly positive signal, but the sale to cover taxes is a standard practice.
Positives
- The acquisition of 70,000 shares through RSUs indicates confidence in the company's future performance by a key executive.
Future Outlook
The RSUs vest over time, with 33.33% vesting on December 1, 2024, and the remaining 66.67% vesting in 8 equal quarterly installments, suggesting a long-term incentive structure for the CFO.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company executives and their confidence in the company's stock.
Stakeholder Impact
- The stock transactions may have a minor impact on shareholders, providing insight into executive compensation and ownership.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | Date of stock transactions (acquisition and disposal). |
| 12/01/2024 | Initial vesting date for 33.33% of the awarded RSUs. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.